Ultrasound-Based Prothesis Allows Intuitive Task Completion, De'Andre Darby, Ananya S
Its currently in phase III clinical trials, which is the final stage before approval
CrossRef Evaluation of the Validity and Usability of the Mobile Application for Early Detection of Metabolic Syndrome: A Cross-Sectional Study Okti Sri Purwanti, Diaz Aziz Pramudita, Agus Sudaryanto, Tanjung Anita Sari Indah Kusmaningrum, Syarif Fathurozaq Wibowo, Ulfa Munawaroh Diniyah, Muhammad Hananfajri Rasyid, Danar Wasis Pambudi, Annisa Niken Larasati, Nimas Zuhrufana Jurnal Berita Ilmu Keperawatan.2026
It is critical to consider existing medications and medical background, as these drugs should not be combined with certain other treatments, including GLP-1 receptor agonists
The claim of a favourable benefit-risk profile seems to be a bit of a judgment call, theres not much more weight loss and not many more other health benefits than with semaglutide 2.4mg and the adverse events, particularly the Dysaesthesia cluster experienced by more than 22% of the 7.2mg group, seem concerning to me
CVOTs primarily proved cardiovascular safety and tolerability of different GLP-1 receptor agonists, but also showed cardiovascular benefit of specific drugs